Epilepsy Research
Volume 30, Issue 1 , Pages 69-76 , March 1998

Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: Comparison with phenytoin

Received 8 October 1997 ,Accepted 29 October 1997.

References 

  1. Albertson TE, Peterson SL, Stark LG. Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats. Neuropharmacology. 1980;19:643–652
  2. Albright PS, Burnham WM. Development of a new pharmacological seizure model: Effects of anticonvulsants on cortical- and amygdala-kindled seizures in the rat. Epilepsia. 1980;21:681–689
  3. Browne TR, Davoudi H, Donn KH, Dougherty CL, Dukes GE, Evans B, et al. Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia. 1989;30(Suppl. 2):S27–S32
  4. Callahan DA, Schwark WS. Pharmacological modification of amygdaloid-kindled seizures. Neuropharmacology. 1980;19:1131–1136
  5. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin in acute treatment of seizures. Neurology. 1978;28:874–880
  6. Ebert U, Rundfeldt C, Löscher W. Sex differences in the anticonvulsant efficacy of phenytoin in amygdala-kindled rats. Brain Res. 1994;638:45–52
  7. Ebert U, Rundfeldt C, Löscher W. Development and pharmacological suppression of secondary afterdischarges in the hippocampus of amygdala-kindled rats. Eur. J. Neurosci. 1995;7:732–741
  8. Ebert U, Cramer S, Löscher W. Phenytoin's effect on the spread of seizure activity in the amygdala kindling model. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997;356:341–347
  9. Ehle AL. Effects of phenytoin on amygdaloid kindled seizures in the rat. Electroencephalogr. Clin. Neurophysiol. 1980;48:102–105
  10. Kutt H, Louis S, McDowell F. Intravenous diphenylhydantoin in experimental seizures. Arch. Neurol. 1968;18:465–477
  11. Leppik IE, Boucher R, Wilder BJ, Murthy VS, Rask CA, Watridge C, et al. Phenytoin prodrug: preclinical and clinical studies. Epilepsia. 1989;30(Suppl. 2):S22–S26
  12. Louis S, Kutt H, McDowell F. The cardiovasculatory changes caused by intravenous dilantin and its solvent. Am. Heart J. 1967;74:523–529
  13. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 1997;53:239–258
  14. Löscher W, Schmidt D. Which animal models should be used in the search of new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145–181
  15. Löscher W, Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37489 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 1991;256:432–440
  16. Löscher W, Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. J. Pharmacol. Exp. Ther. 1991;258:483–489
  17. Löscher W, Jäckel R, Czuczwar SJ. Is amygdala kindling in rats a model for drug-resistant partial epilepsy?. Exp. Neurol. 1986;93:211–226
  18. Löscher W, Rundfeldt C, Hönack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 1993;9:11–18
  19. Lothman EW, Williamson JM, Van Landingham KE. Intraperitoneal phenytoin suppresses kindled responses: effects on motor and electrographic seizures. Epilepsy Res. 1991;9:11–18
  20. Mace JA, Burnham WM. The effect of repeated seizures on anticonvulsant drug response in the kindling model. Electroencephalogr. Clin. Neurophysiol. 1987;67:171–175
  21. McNamara JO. Kindling: an animal model of complex partial epilepsy. Ann. Neurol. 1984;16:S72–76
  22. McNamara JO, Rigsbee LC, Butler LS, Shin C. Intravenous phenytoin is an effective anticonvulsant in the kindling model. Ann. Neurol. 1989;26:675–678
  23. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, Sydney, 1986.
  24. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972;32:281–294
  25. Racine R, Livingston K, Joaquin A. Effects of procaine hydrochloride, diazepam, and diphenylhydantoin on seizure development in cortical and subcortical structures in rats. Electroencephalogr. Clin. Neurophysiol. 1975;38:355–365
  26. Renfrey G, Schlinger H, Jakubow J, Poling A. Effects of phenytoin and phenobarbital on schedule-controlled responding and seizure activity in the amygdala-kindled rat. J. Pharmacol. Exp. Ther. 1989;248:967–973
  27. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol. Rev. 1990;42:223–286
  28. Rundfeldt C, Löscher W. Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J. Pharmacol. Exp. Ther. 1993;266:216–223
  29. Rundfeldt C, Hönack D, Löscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology. 1990;29:845–851
  30. Schmutz M, Klebs K, Baltzer V. Inhibition or enhancement of kindling evolution by antiepileptics. J. Neural. Transm. 1988;72:245–257
  31. Smith RD, Brown BS, Maher RW, Matier WL. Pharmacology of ACC-9653 (phenytoin prodrug). Epilepsia. 1989;30(Suppl. 2):S15–S21
  32. Voits M, Frey HH. Stimulation-dependent effect of antiepileptic drugs in amygdala kindled rats on both seizure score and duration of afterdischarges. Pharmacol. Toxicol. 1994;75:54–61
  33. Wallis W, Kutt H, McDowell F. Intravenous phenytoin in treatment of acute repetitive seizures. Neurology. 1968;18:513–525
  34. Walton NY, Treiman DM. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res. 1990;5:165–168
  35. Wilder BK, Ramsay RE, Willmore J, Feussner GF, Perchalski RJ, Shumate JB. Efficacy of intravenous phenytoin in the treatment of status epilepticus: kinetics and central nervous system penetration. Ann. Neurol. 1977;1:511–518

PII: S0920-1211(97)00098-3

Epilepsy Research
Volume 30, Issue 1 , Pages 69-76 , March 1998

Article Tools

* Image Usage & Resolution